Barinthus Biotherapeutics Corp (BRNS) - מקדם חוב לטווח ארוך להון

The planned use of cash reserves to cover R&D expenses serves as the primary driver of dynamics, which determines the long-term financial dependency ratio for Barinthus Biotherapeutics (BRNS). The value of 0.14 sets the current magnitude of this indicator. Barinthus Biotherapeutics (BRNS) develops cancer vaccines via T-cell therapy and monetizes its intellectual property by selling patents to industry behemoths, ensuring a stream of royalties without capital expenditures.

For Barinthus Biotherapeutics (BRNS), which operates in the stable biotechnology segment, this indicator determines the extent of the company's developmental reliance on borrowed funds. The metric compares liabilities with a maturity of more than one year against net equity. The current value of 0.14 on the GURU.Markets long-term debt-to-equity chart reflects real financial stability. A low ratio confirms the company's autonomy from macroeconomic shocks. It is critical for investors to monitor this balance to minimize interest rate risks.